Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile

Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbanska